The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors
Open accessAbstract
Studies of T cell responses to tumors have focused on the draining lymph node (LN) as the site of activation. We examined the tumor mass as a potential site of activation after adoptive transfer of naive tumor-specific CD8 T cells. Activated CD8 T cells were present in tumors within 24 h of adoptive transfer and proliferation of these cells was also evident 4–5 d later in mice treated with FTY720 to prevent infiltration of cells activated in LNs. To confirm that activation of these T cells occurred in the tumor and not the tumor-draining LNs, we used mice lacking LNs. Activated and proliferating tumor-infiltrating lymphocytes were evident in these mice 24 h and 4 d after naive cell transfer. T cells activated within tumors acquired effector function that was evident both ex vivo and in vivo. Both cross-presenting antigen presenting cells within the tumor and tumor cells directly presenting antigen activated these functional CD8 effectors. We conclude that tumors support the infiltration, activation, and effector differentiation of naive CD8 T cells, despite the presence of immunosuppressive mechanisms. Thus, targeting of T cell activation to tumors may present a tool in the development of cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852 · cited 4×
“…2004; Kortylewski et al., 2005), myeloid-derived suppressor cell (Gabrilovich et al., 2001; Sica and Bronte, 2007), and IDO (Friberg et al., 2002; Munn et al., 2004) have been described for either B16 or LLC. B16 has also been suggested to foster a tolerogenic environment via a CCL21-driven…”
BackgroundInfluentialCD28-mediated co-stimulation: a quantitative support for TCR signalling.
Acuto, O., & Michel, F. (2003) · Nature Reviews Immunology · doi:10.1038/nri1248 · Cited by 775 · cited 2×
“, 1993) can proceed in mice deficient in CD28, suggesting that high TCR occupancy can provide the signal amplification normally provided through CD28 co-stimulation (Acuto and Michel, 2003).”
BackgroundBell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G. M., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. A., & Banchereau, J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1417 · Cited by 544 · cited 9×
“Although not required, TLO and endogenous lymphocytes might enhance naive T cell infiltration and could qualitatively alter the tumor microenvironment by producing chemokines and other inflammatory mediators that could support activation of naive T cells.”
BackgroundInfluentialInduction of potent antitumor immunity by in situ targeting of intratumoral DCs
Furumoto, K., Soares, L., Engleman, E. G., & Merad, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419762 · Cited by 180
Cited by
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., & Krummel, M. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.003 · Cited by 1,026
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C. P., Caramia, F., Salgado, R., Byrne, D. J., Teo, Z. L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0078-7 · Cited by 992
Dendritic Cells and Cancer Immunity
Gardner, A., & Ruffell, B. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.006 · Cited by 907
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
Harjunpää, H., Llort Asens, M., Guenther, C., & Fagerholm, S. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01078 · Cited by 764
Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression
Zamarron, B. F., & Chen, W. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.651 · Cited by 681
Goc, J., Germain, C., Vo-Bourgais, T. K. D., Lupo, A., Klein, C., Knockaert, S., de Chaisemartin, L., Ouakrim, H., Becht, E., Alifano, M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1342 · Cited by 677
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Böttcher, J. P., & Reis e Sousa, C. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.09.001 · Cited by 607
The Roles of CD8+ T Cell Subsets in Antitumor Immunity
St. Paul, M., & Ohashi, P. S. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.06.003 · Cited by 609
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W., Wang, J., Wang, X., & Fu, Y.-X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 472
Self-citationBiological functions of lymphatic vessels
Petrova, T. V., & Koh, G. Y. (2020) · Science · doi:10.1126/science.aax4063 · Cited by 457
Innate immune signaling and regulation in cancer immunotherapy
Corrales, L., Matson, V., Flood, B., Spranger, S., & Gajewski, T. F. (2017) · Cell Research · doi:10.1038/cr.2016.149 · Cited by 408
Dovedi, S. J., Cheadle, E. J., Popple, A. L., Poon, E., Morrow, M., Stewart, R., Yusko, E. C., Sanders, C. M., Vignali, M., Emerson, R. O., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1673 · Cited by 370
Dendritic Cells in the Cancer Microenvironment
Ma, Y., Shurin, G. V., Peiyuan, Z., & Shurin, M. R. (2013) · Journal of Cancer · doi:10.7150/jca.5046 · Cited by 361
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 357
Lund, A. W., Duraes, F. V., Hirosue, S., Raghavan, V. R., Nembrini, C., Thomas, S. N., Issa, A., Hugues, S., & Swartz, M. A. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.01.005 · Cited by 341
Johansson-Percival, A., He, B., Li, Z.-J., Kjellén, A., Russell, K., Li, J., Larma, I., & Ganss, R. (2017) · Nature Immunology · doi:10.1038/ni.3836 · Cited by 331
The role of dendritic cells in cancer and anti-tumor immunity
Marciscano, A. E., & Anandasabapathy, N. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101481 · Cited by 298
Tertiary lymphoid structures in anticancer immunity
Teillaud, J.-L., Houel, A., Panouillot, M., Riffard, C., & Dieu-Nosjean, M.-C. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00728-0 · Cited by 293
Rodriguez, A. B., Peske, J. D., Woods, A. N., Leick, K. M., Mauldin, I. S., Meneveau, M. O., Young, S. J., Lindsay, R. S., Melssen, M. M., Cyranowski, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109422 · Cited by 271
Self-citationAntigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
Sánchez-Paulete, A. R., Teijeira, A., Cueto, F. J., Garasa, S., Pérez-Gracia, J. L., Sánchez-Arráez, A., Sancho, D., & Melero, I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx237 · Cited by 267
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma
Fankhauser, M., Broggi, M. A. S., Potin, L., Bordry, N., Jeanbart, L., Lund, A. W., Da Costa, E., Hauert, S., Rincon-Restrepo, M., Tremblay, C., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4712 · Cited by 259
Effector, Memory, and Dysfunctional CD8+T Cell Fates in the Antitumor Immune Response
Reiser, J., & Banerjee, A. (2016) · Journal of Immunology Research · doi:10.1155/2016/8941260 · Cited by 255
Lecoultre, M., Dutoit, V., & Walker, P. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001408 · Cited by 223
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
Oh, K., Park, H.-B., Byoun, O.-J., Shin, D.-M., Jeong, E. M., Kim, Y. W., Kim, Y. S., Melino, G., Kim, I.-G., & Lee, D.-S. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101457 · Cited by 118
“In this study, naive CD8+ T cells were activated both by tumor cells themselves and by cross-presenting antigen-presenting cells within the tumor (Thompson et al., 2010).”
BackgroundEndoplasmic Reticulum Stress Contributes to Mitochondrial Exhaustion of CD8+ T Cells
Hurst, K. E., Lawrence, K. A., Essman, M. T., Walton, Z. J., Leddy, L. R., & Thaxton, J. E. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0182 · Cited by 102
Type I IFN activating type I dendritic cells for antitumor immunity
Liang, Y., Hannan, R., & Fu, Y.-X. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2564 · Cited by 91
“cDC1s lie within both peripheral lymphoid and tumor tissues; CD8þ T-cell reactivation can occur within both sites (8, 9).”
BackgroundSelf-citationThe 12-CK Score: Global Measurement of Tertiary Lymphoid Structures
Li, R., Berglund, A., Zemp, L., Dhillon, J., Putney, R., Kim, Y., Jain, R. K., Grass, G. D., Conejo-Garcia, J., & Mulé, J. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694079 · Cited by 39
Shaping of Peripheral T Cell Responses by Lymphatic Endothelial Cells
Humbert, M., Hugues, S., & Dubrot, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00684 · Cited by 32
“Although T cell receptor (TCR)-transgenic tumor-infiltrating naïve T cells may be activated in situ (62), it is unlikely, given the immunosuppressive tumor-related environment, that this will lead to fully competent effector T cell differentiation.”
BackgroundFamta, P., Shah, S., Vambhurkar, G., Pandey, G., Bagasariya, D., Kumar, K. C., Prasad, S. B., Shinde, A., Wagh, S., Srinivasarao, D. A., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01669-9 · Cited by 21
Metadata
- Authors
- Thompson, E. D., Enriquez, H. L., Fu, Y.-X., & Engelhard, V. H.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-07-26
- Volume
- 207
- Issue
- 8
- Pages
- 1791-1804
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2143118772
- Cited by
- 249
- References
- 7
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.